Key Drivers
- Margin strength
- Strong cash flow
- Premium valuation
AIAI Summary
ResMed now looks more like a premium cash compounder than a simple device supplier, but at ~30x earnings the stock only works if management keeps delivering high-quality compounding through core share gains and adjacent growth initiatives while proving GLP-1 and competitive threats do not cap the runway.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin strength
- •Strong cash flow
- •Premium valuation
RMD combines strong profitability, cash flow, and balance-sheet quality, but its premium valuation and intangibles-heavy book value limit upside.
Price Behavior
Key Price Behavior Insights:
- •Uptrend breakout
- •Support holding
- •Near-term stretch
RMD has rebounded sharply from the $182.82 low to $209.63, turning the short-term trend upward with $200 now acting as support, but it is pressing into near-term resistance at $209.86 and could pause if momentum fades.
Sharp recovery from $182.82 to $209.63 suggests a fast, stretched rally
Sentiment & News
Key News Insights:
- •Growth Drivers
- •Valuation Gap
- •Analyst Upside
ResMed's recent coverage has been broadly positive on growth, innovation, and analyst upside, but near-term headwinds and mixed analyst views keep valuation and the upcoming Aug. 6 earnings report in focus.
Overall, the news flow supports a constructive outlook for RMD, with positive fundamentals and sentiment offset by macro and competitive risks
Similar Companies in Healthcare
Other companies in the same sector with AI ratings